Suppr超能文献

恶唑烷酮类作为抗结核药物的最新进展。

Recent advances in oxazolidinones as antituberculosis agents.

作者信息

Lu Haijia, Wang Huahao, Zhao Hongyi, Zhang Dongfeng

机构信息

Beijing Key Laboratory of Active Substance Discovery & Druggability Evaluation, Chinese Academy of Medical Sciences Key Laboratory of Anti-DR TB Innovative Drug Research, Institute of Materia Medica, Peking Union Medical College & Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing, 100050, China.

出版信息

Future Med Chem. 2022 Aug;14(15):1149-1165. doi: 10.4155/fmc-2022-0079. Epub 2022 Jul 22.

Abstract

Tuberculosis (TB) is an infectious and fatal disease caused by () and remains a serious public health threat; therefore, the development of new antitubercular agents is a priority for the World Health Organization's End TB strategy and the United Nations' Sustainable Development Goals to eradicate TB. Oxazolidinones are a class of synthetic antibacterial agents with a distinct mode of action developed for the treatment of Gram-positive bacterial infections. Many oxazolidinones exhibit good activity against , and some are currently in clinical trials for multidrug-resistant TB and extensively drug-resistant TB therapy. In this review, the mechanism of action, activity and toxicity of oxazolidinones and recent progress in the research and development of oxazolidinones as anti-TB agents are summarized.

摘要

结核病(TB)是由()引起的一种传染性致命疾病,仍然是严重的公共卫生威胁;因此,开发新型抗结核药物是世界卫生组织终结结核病战略和联合国消除结核病可持续发展目标的优先事项。恶唑烷酮类是一类具有独特作用方式的合成抗菌剂,用于治疗革兰氏阳性菌感染。许多恶唑烷酮类对()表现出良好活性,一些目前正处于耐多药结核病和广泛耐药结核病治疗的临床试验中。在本综述中,总结了恶唑烷酮类的作用机制、活性和毒性以及作为抗结核药物的研发最新进展。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验